Cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with antiestrogen therapy work to combat endocrine resistance in women with estrogen ER+ metastatic breast cancer. One CDK 4/6 inhibitor is FDA approved and 2 others are in Phase 3 development for breast cancer. This activity discusses clinical data on the efficacy and safety of the FDA-approved CDK 4/6 inhibitor, palbociclib, in combination with letrozole in ER+ metastatic breast cancer.
A continuing education program related to this video is offered at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7170
© 2016 Imedex, LLC.
Advertisement